keyword
MENU ▼
Read by QxMD icon Read
search

Secukinumab

keyword
https://www.readbyqxmd.com/read/28809988/methods-for-imputing-missing-efficacy-data-in-clinical-trials-of-biologic-psoriasis-therapies-implications-for-interpretations-of-trial-results
#1
Richard G B Langley, Kristian Reich, Charis Papavassilis, Todd Fox, Yankun Gong, Achim Gu Ttner
<p>BACKGROUND: An issue in long-term clinical trials of biologics in psoriasis is how to handle missing efficacy data. This methodological challenge may not be understood by clinicians, yet can have a significant effect on the interpretation of clinical trials.</p> <p>OBJECTIVE Evaluate the effects of different data imputation methods on apparent secukinumab response rates.</p> <p>METHODS: Post hoc analyses were conducted on efficacy data from 2 phase III, multicenter, randomized, double-blind trials (FIXTURE and ERASURE) of secukinumab in moderate to severe plaque psoriasis...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28794572/refractory-psoriasis-vulgaris-with-itching-successfully-treated-with-the-anti-interleukin-17a-antibody-secukinumab-a-case-of-secondary-failure-of-other-biologic-agents
#2
Yuko Kurosaki, Kenji Takamori, Yasushi Suga
No abstract text is available yet for this article.
July 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28791896/biologics-that-inhibit-the-th17-pathway-and-related-cytokines-to-treat-inflammatory-disorders
#3
Anna Balato, Emanuele Scala, Nicola Balato, Giuseppina Caiazzo, Roberta Di Caprio, Giuseppe Monfrecola, Annunziata Raimondo, Serena Lembo, Fabio Ayala
Advances in the understanding of TNF-α and IL-17 synergistic functions have recently led to the concept that patients who do not respond or who respond inadequately to TNF-α inhibitors may have IL-17-driven diseases, opening up the way for a new class of therapeutic development: Th17-inhibitors. Areas covered: In this review, the authors discuss the central role that the IL-23/Th17 axis plays in the pathogenesis of several inflammatory diseases, such as psoriasis, highlighting its position as a relevant therapeutic target...
August 9, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28791450/relative-efficacy-and-safety-of-apremilast-secukinumab-and-ustekinumab-for-the-treatment-of-psoriatic-arthritis
#4
G G Song, Y H Lee
OBJECTIVE: To assess the relative efficacy and safety of apremilast, secukinumab, and ustekinumab at different doses in patients with active psoriatic arthritis (PsA). METHOD: A Bayesian network meta-analysis was conducted, which included randomized controlled trials (RCTs) that examined the efficacy and safety of apremilast 20 mg, apremilast 30 mg, secukinumab 75 mg, secukinumab 150 mg, secukinumab 300 mg, ustekinumab 45 mg, and ustekinumab 90 mg compared with placebo...
August 8, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28780364/the-effect-of-secukinumab-on-moderate-to-severe-scalp-psoriasis-results-of-a-24-week-randomized-double-blind-placebo-controlled-phase-3b-study
#5
Jerry Bagel, Kristina Callis Duffin, Angela Moore, Laura K Ferris, Kimberly Siu, Jennifer Steadman, Farid Kianifard, Judit Nyirady, Mark Lebwohl
BACKGROUND: Moderate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-severe body psoriasis. OBJECTIVE: Evaluate the efficacy and safety of secukinumab in moderate-to-severe scalp psoriasis. METHODS: In this 24-week, double-blind, phase 3b study, 102 patients were randomized 1:1 to subcutaneous secukinumab 300 mg or placebo at baseline, weeks 1, 2, and 3, and then every 4 weeks from week 4 to 20...
August 2, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28768308/secukinumab-induced-psoriasiform-eruption
#6
Michael J Sladden, Christopher S Sladden, Wayne P F Gulliver
No abstract text is available yet for this article.
August 2, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28765121/novel-therapies-for-immune-mediated-inflammatory-diseases-what-can-we-learn-from-their-use-in-rheumatoid-arthritis-spondyloarthritis-systemic-lupus-erythematosus-psoriasis-crohn-s-disease-and-ulcerative-colitis
#7
REVIEW
Kenneth F Baker, John D Isaacs
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. As well as providing superior treatments for immune-mediated inflammatory diseases (IMIDs), such therapies also offer unrivalled opportunities to study the underlying immunopathological basis of these conditions.In this review, we explore recent approaches to the treatment of IMIDs and the insights to pathobiology that they provide...
August 1, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28762213/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis-a-matching-adjusted-indirect-comparison
#8
Vibeke Strand, Keith A Betts, Manish Mittal, Jinlin Song, Martha Skup, Avani Joshi
INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA. METHODS: A matching-adjusted indirect comparison was conducted using individual patient data from the ADEPT trial of adalimumab and published data from FUTURE I and II...
July 31, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28760056/cost-per-additional-responder-for-ixekizumab-and-other-fda-approved-biologics-in-moderate-to-severe-plaque-psoriasis
#9
Sarah Al Sawah, Shonda A Foster, Russel Burge, David Amato, Alexander Schacht, Baojin Zhu, Susanne Hartz, Craig Leonardi
BACKGROUND: Evidence of the cost-efficacy of ixekizumab for the treatment of moderate-to-severe plaque psoriasis (PsO) in the United States (US) is limited. OBJECTIVE: To estimate the number needed to treat (NNT) and monthly cost of achieving one additional Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responder for ixekizumab and other Food and Drug Administration (FDA)-approved biologics in PsO. METHODS: A network meta-analysis estimated the probability of achieving PASI 75, 90, or 100 response during induction for each biologic...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28755058/novel-biologic-agents-targeting-interleukin-23-and-interleukin-17-for-moderate-to-severe-psoriasis
#10
REVIEW
Zeyu Chen, Yu Gong, Yuling Shi
Psoriasis is a common, chronic inflammatory skin disease and cannot be cured. The treatment of moderate-to-severe plaque psoriasis has been revolutionized with the development of biologic agents for nearly 20 years. Current studies show that interleukin-23 and interleukin-17 play remarkable roles in the pathogenesis of psoriasis. Interleukin-23 can sustain the differentiation and maintenance of T helper-17 lineage. Interleukin-17 can recruit and stimulate many cells, which play important parts in psoriasis through interacting with the interleukin-17 receptor...
July 28, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28752230/biological-therapies-for-the-treatment-of-beh%C3%A3-et-s-disease-related-uveitis-beyond-tnf-alpha-blockade-a-narrative-review
#11
REVIEW
Jurgen Sota, Donato Rigante, Giuseppe Lopalco, Bruno Frediani, Rossella Franceschini, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Claudia Fabiani, Luca Cantarini
Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab...
July 27, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28744098/spotlight-on-brodalumab-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-design-development-and-potential-place-in-therapy
#12
REVIEW
Michael Roman, Melvin W Chiu
Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA. The role of IL-17A in the pathogenesis of psoriasis, as well as the remarkable effectiveness of IL-17 inhibitors in the treatment of moderate-to-severe plaque psoriasis, is well established. The mechanism of action of brodalumab is unique in that it inhibits the IL-17 receptor compared to the two other currently FDA-approved IL-17 inhibitors, secukinumab and ixekizumab, which inhibit the IL-17A molecule itself...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28737440/secukinumab-improves-scalp-pain-itching-scaling-and-quality-of-life-in-patients-with-moderate-to-severe-scalp-psoriasis
#13
Steven R Feldman, Lawrence Green, Alexa B Kimball, Kimberly Siu, Yang Zhao, Vivian Herrera, Judit Nyirady, Andrew F Alexis
INTRODUCTION: Scalp psoriasis adversely affects patients' lives and is often resistant to treatment however it has not been a major focus of a clinical study. This analysis assessed the effect of secukinumab on patient-reported outcomes (PRO) of scalp psoriasis. METHODS: A randomized, double-blind, placebo-controlled, multicenter study was conducted in 102 adult patients with moderate-to-severe scalp psoriasis. Patients were randomized 1:1 to secukinumab 300mg or placebo...
July 24, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28735569/treatment-of-moderate-to-severe-psoriasis-with-high-dose-450-mg-secukinumab-case-reports-of-off-label-use
#14
Jennifer Beecker, Jiyeh Joo
Treatment of moderate to severe psoriasis often requires systemic therapy, including biologics. Partial response to biologics and relapses are commonly managed with dose escalation. Secukinumab is a relatively new biologic that is currently used to treat moderate to severe psoriasis. There has been no literature published on dose escalation of secukinumab. This article describes the off-label use of a higher dose of secukinumab (450 mg every 4 weeks) instead of the standard dosing (300 mg every 4 weeks) in 2 patients with moderate to severe psoriasis...
July 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28733978/severe-subcutaneous-hematoma-in-a-patient-with-psoriatic-arthritis-changes-of-platelet-count-in-psoriatic-patients-with-biologic-agents
#15
Yuka Maya, Yasuyuki Fujita, Chihiro Nakayama, Shinya Kitamura, Hiroo Hata, Ken Arita, Hiroshi Shimizu
The effectiveness of biologics has changed therapeutic strategies for psoriasis dramatically, but biologics are known to have various adverse effects. We report a 63-year-old woman with psoriatic arthritis who suddenly developed a subcutaneous hematoma after being successfully treated with adalimumab. As she had also suffered from alcoholic cirrhosis, we speculated that she had developed thrombocytopenia severe enough to cause a subcutaneous hematoma. Furthermore, we investigated the changes of platelet counts in 65 psoriatic patients treated with biologics at a single institute from 2010 to 2016...
July 22, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28732152/secukinumab-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-a-review-of-the-literature
#16
M Abrouk, J Gandy, M Nakamura, K Lee, M Brodsky, R Singh, H Zhu, B Farahnik, T Bhutani, J Koo
While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities. In the recent past, there has been increasing evidence that interleukin (IL)-17 plays a vital role in the pathophysiology of psoriasis. Preclinical, phase II, and phase III studies of secukinumab (Cosentyx®) targeting IL-17 and its receptor have thus far proved to be promising. We reviewed the results of phase II and phase III clinical trials for secukinumab in the treatment of psoriasis and psoriatic arthritis...
July 2017: Skin Therapy Letter
https://www.readbyqxmd.com/read/28695989/efficacy-and-safety-of-secukinumab-in-treating-moderate-to-severe-plaque-psoriasis-in-two-real-world-canadian-dermatology-clinics-a-multicenter-retrospective-study
#17
J R Georgakopoulos, A Ighani, L L Zhou, J Yeung
Secukinumab is an interleukin (IL)-17A antagonist approved in 2015 by health agencies around the world for the treatment of moderate to severe plaque psoriasis in adult patients. Current knowledge of the efficacy and safety of secukinumab is limited to data from phase III randomized controlled trials (RCT). Despite the acceptable safety profile and promising efficacy results, there remains to be a lack of understanding of treatment outcomes in real-world clinical practice. This article is protected by copyright...
July 11, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28667056/endogenous-endophthalmitis-and-osteomyelitis-associated-with-interleukin-17-inhibitor-treatment-for-psoriasis-in-a-patient-with-diabetes
#18
Christine E Martinez, John B Allen, Frederick H Davidorf, Colleen M Cebulla
A 64-year-old man with type 2 diabetes mellitus and plaque psoriasis presented to the emergency room with 3 days of progressive right eye pain and decreased vision. After extensive workup and multidisciplinary team effort, the patient was diagnosed with and treated for unilateral endogenous methicillin-sensitive Staphylococcus aureus endophthalmitis, bacteraemia and osteomyelitis of the foot. The patient had been started on the interleukin 17 (IL-17) inhibitor secukinumab for his treatment-resistant plaque psoriasis 4 weeks prior to presentation...
June 29, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28654150/severe-hidradenitis-suppurativa-responding-to-treatment-with-secukinumab-a-case-report
#19
L Thorlacius, P Theut Riis, G B E Jemec
An inappropriate immunologic response to an unknown antigen has been suggested to play a role in the pathogenesis of Hidradenitis suppurativa (HS). Studies have identified elevated levels of several proinflammatory cytokines, including IL-17A and TNF-α, nominating these as possible therapeutic targets.(1) Secukinumab is an Il-17A monoclonal antibody, which binds to Il-17A and inhibits the cytokine interaction with the Il-17 receptors, inhibiting the inflammatory cascade. Here we report on a case of a 47-year-old man, with Hurley Stage III lesions at the neck, axillae, breasts, genital skin and buttocks, who had experienced only temporary benefit from different medical treatments over the years...
June 27, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28650001/brodalumab-the-first-anti-il-17-receptor-agent-for-psoriasis
#20
L Puig
Psoriasis is a chronic immune-mediated inflammatory skin disease in which the alteration of the interleukin-23 (IL-23)/IL-17 cytokine axis appears to be crucial from a pathogenetic perspective. This has been confirmed by the efficacy of monoclonal antibodies blocking IL-17A, such as secukinumab and ixekizumab. Brodalumab is a human anti-IL-17 receptor A (IL-17RA) monoclonal antibody that inhibits the biological activity of IL-17A, IL-17F and other IL-17 isoforms, and has been approved (210 mg s.c. at weeks 0, 1, 2 and every 2 weeks thereafter) for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma in Japan (Lumicef)...
May 2017: Drugs of Today
keyword
keyword
30575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"